An innovative Chinese Alzheimer's drug that hit the domestic market last week, will go through clinical trials on 2,000 patients overseas in 2020.

OCT 23 (AP/UNB) -- Biogen Inc. said Tuesday it will seek federal approval for a medicine to treat early Alzheimer's disease, a landmark step toward finding a treatment that can alter the course of the most common form of dementia.